Computational methods and systems to bolster an immune response

• US 20070196362A1
• Filed: 03/28/2007
• Published: 08/23/2007
• Est. Priority Date: 08/24/2004
• Status: Abandoned Application

• Current Assignee: Searete LLC (Intellectual Ventures LLC)
• Original Assignee: Searete LLC (Intellectual Ventures LLC)
• Inventors: Jung, Edward, Wilson, Richa, Sweeney, Elizabeth, Bangera, Mahalaxmi, Myhrvold, Nathan, Wood, Lowell, Ishikawa, Muriel
• Application Number:
  US11/729,958
• Publication Number:
  US 20070196362A1
• Time in Patent Office: Days
• US Class Current: 424/130.1
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: G16H 50/20 for computer-aided diagnosis, e.g. based on medical expert systems
• CPC Class Codes: G16Z 99/00 Subject matter not provided for in other main groups of this subclass
• CPC Class Codes: Y02A 90/10 Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Abstract

The present application relates, in general, to a system and/or method for detection and/or treatment.

Claims

1. A method, comprising:

providing one or more computable attributes of one or more agents associated with at least a part of an immune response in a host; and

forming a set of the one or more computable attributes operable for modulating the at least a part of the immune response in the host.

2. The method of claim 1, wherein the forming a set of the one or more computable attributes further comprises:

forming a set including one or more computable attributes with a sequence match to the host.

3. The method of claim 2, wherein the sequence match comprises:

at least one of an amino acid, a nucleic acid, or a sugar sequence match.

4. The method of claim 1, wherein the forming a set of the one or more computable attributes further comprises:

forming a set including at least one substantially non-linear computable epitope.

5. The method of claim 1, wherein the forming a set of the one or more computable attributes operable for modulating the at least a part of the immune response in the host includes forming a set of the one or more computable attributes of the one or more agents amenable to a treatment, wherein the treatment includes:

a treatment of at least a part of at least one humanized antibody.

6. The method of claim 1, wherein the forming a set of the one or more computable attributes operable for modulating the at least a part of the immune response in the host includes forming a set of the one or more computable attributes of the one or more agents amenable to a treatment, wherein the treatment includes:

a treatment of at least a part of at least one of a T-lymphocyte, a killer T-lymphocyte, a helper T-lymphocyte, a cytotoxic T-lymphocyte, a T-8 lymphocyte, a Cluster of Differentiation (CD) molecule, a CD3 molecule, or a CD1 molecule.

7. The method of claim 1, wherein the forming a set of the one or more computable attributes operable for modulating the at least a part of the immune response in the host includes forming a set of the one or more computable attributes of the one or more agents amenable to a treatment, wherein the treatment includes:

a treatment of at least one modulator of at least one humanized antibody.

8. The method of claim 1, wherein the forming a set of the one or more computable attributes operable for modulating the at least a part of the immune response in the host includes forming a set of the one or more computable attributes of the one or more agents amenable to a treatment, wherein the treatment includes:

a treatment of at least one modulator of at least a part of at least one of a T-lymphocyte, a killer T-lymphocyte, a helper T-lymphocyte, a cytotoxic T-lymphocyte, a T-8 lymphocyte, a Cluster of Differentiation (CD) molecule, a CD3 molecule, or a CD1 molecule.

9. The method of claim 1, wherein the forming a set of the one or more computable attributes operable for modulating the at least a part of the immune response in the host includes forming a set of the one or more computable attributes of the one or more agents amenable to a treatment, wherein the treatment includes:

a treatment of at least a part of a B-lymphocyte.

10. The method of claim 1, wherein the forming a set of the one or more computable attributes operable for modulating the at least a part of the immune response in the host includes forming a set of the one or more computable attributes of the one or more agents amenable to a treatment, wherein the treatment includes:

a treatment of at least one modulator of at least a part of a B-lymphocyte.

11. The method of claim 1, wherein the forming a set of the one or more computable attributes operable for modulating the at least a part of the immune response in the host includes forming a set of the one or more computable attributes of the one or more agents amenable to a treatment, wherein the treatment includes:

a treatment directed to at least one of a glycoprotein or a receptor ligand.

12. The method of claim 1, wherein the forming a set of the one or more computable attributes operable for modulating the at least a part of the immune response in the host includes forming a set of the one or more computable attributes of the one or more agents amenable to a treatment, wherein the treatment includes:

a treatment including at least one modulator of (a) an epitopic shift or (b) an epitopic drift predicted in the one or more agents.

13. The method of claim 12, wherein the treatment including at least one modulator of (a) an epitopic shift or (b) an epitopic drift predicted in the one or more agents includes:

at least one suppressor of mutational alteration of the one or more agents.

14. The method of claim 12, wherein the treatment including at least one modulator of (a) an epitopic shift or (b) an epitopic drift predicted in the one or more agents includes:

at least one interfering nucleic acid.

15. A system, comprising:

circuitry for providing one or more computable attributes of one or more agents associated with at least a part of an immune response in a host; and

circuitry for forming a set of the one or more computable attributes operable for modulating the at least a part of the immune response in the host.

16. The system of claim 15, wherein the circuitry for forming a set of the one or more computable attributes further comprises:

circuitry for forming a set including one or more computable attributes with a sequence match to the host.

17. The system of claim 16, wherein the sequence match comprises:

at least one of an amino acid, a nucleic acid, or a sugar sequence match.

18. The system of claim 15, wherein the circuitry for forming a set of the one or more computable attributes further comprises:

circuitry for forming a set including at least one substantially non-linear computable epitope.

19. The system of claim 15, wherein the circuitry for forming a set of the one or more computable attributes operable for modulating the at least a part of the immune response of the host includes circuitry for forming a set of the one or more computable attributes of the one or more agents amenable to a treatment, wherein the treatment includes:

a treatment of at least a part of at least one humanized antibody.

20. The system of claim 15, wherein the circuitry for forming a set of the one or more computable attributes operable for modulating the at least a part of the immune response of the host includes circuitry for forming a set of the one or more computable attributes of the one or more agents amenable to a treatment, wherein the treatment includes:

a treatment of at least a part of at least one of a T-lymphocyte, a killer T-lymphocyte, a helper T-lymphocyte, a cytotoxic T-lymphocyte, a T-8 lymphocyte, a Cluster of Differentiation (CD) molecule, a CD3 molecule, or a CD1 molecule.

21. The system of claim 15, wherein the circuitry for forming a set of the one or more computable attributes operable for modulating the at least a part of the immune response of the host includes circuitry for forming a set of the one or more computable attributes of the one or more agents amenable to a treatment, wherein the treatment includes:

a treatment of at least one modulator of a humanized antibody.

22. The system of claim 15, wherein the circuitry for forming a set of the one or more computable attributes operable for modulating the at least a part of the immune response of the host includes circuitry for forming a set of the one or more computable attributes of the one or more agents amenable to a treatment, wherein the treatment includes:

a treatment of at least one modulator of at least a part of at least one of a T-lymphocyte, a killer T-lymphocyte, a helper T-lymphocyte, a cytotoxic T-lymphocyte, a T-8 lymphocyte, a Cluster of Differentiation (CD) molecule, a CD3 molecule, or a CD1 molecule.

23. The system of claim 15, wherein the circuitry for forming a set of the one or more computable attributes operable for modulating the at least a part of the immune response of the host includes circuitry for forming a set of the one or more computable attributes of the one or more agents amenable to a treatment, wherein the treatment includes:

a treatment of at least a part of a B-lymphocyte.

24. The system of claim 15, wherein the circuitry for forming a set of the one or more computable attributes operable for modulating the at least a part of the immune response of the host includes circuitry for forming a set of the one or more computable attributes of the one or more agents amenable to a treatment, wherein the treatment includes:

a treatment of at least one modulator of at least a part of a B-lymphocyte.

25. The system of claim 15, wherein the circuitry for forming a set of the one or more computable attributes operable for modulating the at least a part of the immune response of the host includes circuitry for forming a set of the one or more computable attributes of the one or more agents amenable to a treatment, wherein the treatment includes:

a treatment directed to at least one of a secreted protein, a glycoprotein, or a receptor ligand.

26. The system of claim 15, wherein the circuitry for forming a set of the one or more computable attributes operable for modulating the at least a part of the immune response of the host includes circuitry for forming a set of the one or more computable attributes of the one or more agents amenable to a treatment, wherein the treatment includes:

a treatment including at least one modulator of (a) an epitopic shift or (b) an epitopic drift predicted in the at least one agent.

27. The system of claim 26, wherein the treatment including at least one modulator of (a) an epitopic shift or (b) an epitopic drift predicted in the at least one agent includes:

at least one suppressor of mutational alteration of the at least one agent.

28. The method of claim 26, wherein the treatment including at least one modulator of (a) an epitopic shift or (b) an epitopic drift predicted in the at least one agent includes:

at least one interfering nucleic acid.

29. A method, comprising:

delivering a treatment to a host wherein the treatment is associated with modulating a predicted pattern of progression of one or more computable epitopes.

30. The method of claim 29, wherein the treatment further comprises:

delivering a treatment of at least a part of one or more of a T-lymphocyte, a killer T-lymphocyte, a helper T-lymphocyte, a cytotoxic T-lymphocyte, a T-8 lymphocyte, a Cluster of Differentiation (CD) molecule, a CD3 molecule, or a CD1 molecule.

31. The method of claim 29, wherein the treatment further comprises:

delivering a treatment of one or more modulators of at least a part of at least one of a T-lymphocyte, a killer T-lymphocyte, a helper T-lymphocyte, a cytotoxic T-lymphocyte, a T-8 lymphocyte, a Cluster of Differentiation (CD) molecule, a CD3 molecule, or a CD1 molecule.

32. The method of claim 29, wherein the treatment further comprises:

delivering a treatment of at least a part of a B-lymphocyte.

33. The method of claim 29, wherein the treatment further comprises

delivering a treatment of at least one modulator of at least a part of a B-lymphocyte.

34. The method of claim 29, wherein the treatment further comprises:

delivering a treatment of at least a part of at least one humanized antibody.

35. The method of claim 29, wherein the treatment further comprises:

delivering a treatment of one or more modulators of at least a part of at least one humanized antibody.

36. The method of claim 29, wherein the delivering a treatment to a host further comprises:

delivering a treatment directed to at least one of a secreted protein, a glycoprotein, and/or a receptor ligand.

37. The method of claim 29, wherein the delivering a treatment to a host further comprises:

delivering a treatment including at least one modulator of (a) an epitopic shift or (b) an epitopic drift predicted in at least one agent.

38. The method of claim 37, wherein the delivering a treatment including at least one modulator of (a) an epitopic shift or (b) an epitopic drift predicted in at least one agent includes:

at least one suppressor of mutational alteration of the at least one agent.

39. The method of claim 37, wherein the delivering a treatment including at least one modulator of (a) an epitopic shift or (b) an epitopic drift predicted in at least one agent includes:

at least one interfering nucleic acid or nucleic acid sequence.

40. A system comprising:

circuitry for suggesting delivery of a treatment to a host wherein the treatment is associated with modulating a predicted pattern of progression of one or more computable epitopes.

41. The system of claim 40, wherein the circuitry for suggesting delivery of a treatment further comprises:

circuitry for suggesting delivery of a treatment of at least a part of one or more of a T-lymphocyte, a killer T-lymphocyte, a helper T-lymphocyte, a cytotoxic T-lymphocyte, a T-8 lymphocyte, a Cluster of Differentiation (CD) molecule, a CD3 molecule, or a CD1 molecule.

42. The system of claim 40, wherein the circuitry for suggesting delivery of a treatment further comprises:

circuitry for suggesting delivery of a treatment of one or more modulators of at least a part of at least one of a T-lymphocyte, a killer T-lymphocyte, a helper T-lymphocyte, a cytotoxic T-lymphocyte, a T-8 lymphocyte, a Cluster of Differentiation (CD) molecule, a CD3 molecule, or a CD1 molecule.

43. The system of claim 40, wherein the circuitry for suggesting delivery of a treatment further comprises:

circuitry for suggesting delivery of a treatment of at least a part of a B-lymphocyte.

44. The system of claim 40, wherein the circuitry for suggesting delivery of a treatment further comprises:

circuitry for suggesting delivery of a treatment of at least one modulator of at least a part of a B-lymphocyte.

45. The system of claim 40, wherein the circuitry for suggesting delivery of a treatment further comprises:

circuitry for suggesting delivery of a treatment of at least a part of at least one humanized antibody.

46. The system of claim 40, wherein the circuitry for suggesting delivery of a treatment further comprises:

circuitry for suggesting delivery of a treatment of one or more modulators of at least a part of at least one humanized antibody.

47. The system of claim 40, wherein the circuitry for suggesting delivery of a treatment further comprises:

circuitry for suggesting delivery of a treatment directed to at least one of a secreted protein, a glycoprotein, or a receptor ligand.

48. The system of claim 40, wherein the circuitry for suggesting delivery of a treatment further comprises:

circuitry for suggesting delivery of a treatment including at least one modulator of (a) an epitopic shift or (b) an epitopic drift predicted in at least one agent.

49. The system of claim 48, wherein the circuitry for suggesting delivery of a treatment including at least one modulator of (a) an epitopic shift or (b) an epitopic drift predicted in at least one agent further comprises:

at least one suppressor of mutational alteration of the at least one agent.

50. The system of claim 48, wherein the circuitry for suggesting delivery of a treatment including at least one modulator of (a) an epitopic shift or (b) an epitopic drift predicted in at least one agent further comprises:

at least one interfering nucleic acid or nucleic acid sequence.